QUILT 502 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,428 results for “QUILT 502”

ImmunityBio Initiates Phase I Trial of CD19-Targeted haNK Cell Therapy for NHL in South Africa

ImmunityBio Partners with nCartes to Streamline Clinical Trial Data Collection Through EMR Automation

Quilt Health Secures $6M Seed Funding to Modernize Clinical Trial Access for Complex Diseases

Anktiva Plus BCG Shows High Response in BCG-Unresponsive NMIBC

FDA Updates Draft Guidance on Drug and Device Manufacturer Communications with Payors, Incorporating PIE Act Provisions

ImmunityBio Initiates Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma

ImmunityBio's Anktiva Pursues European and UK Approval for BCG-Unresponsive Bladder Cancer

ImmunityBio Launches Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma

ImmunityBio's Anktiva Receives EMA Review for Bladder Cancer Treatment

ANKTIVA Receives Permanent J-Code from CMS, Streamlining Reimbursement for Bladder Cancer Treatment

Page 1 of 61